- Home
- BIIB vs HBAN Comparison
BIIB vs HBAN Comparison
Compare BIIB & HBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HBAN
- Stock Information
- Founded
- BIIB 1978
- HBAN 1866
- Country
- BIIB United States
- HBAN United States
- Employees
- BIIB N/A
- HBAN N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HBAN Major Banks
- Sector
- BIIB Health Care
- HBAN Finance
- Exchange
- BIIB Nasdaq
- HBAN Nasdaq
- Market Cap
- BIIB 25.1B
- HBAN 25.7B
- IPO Year
- BIIB 1991
- HBAN N/A
- Fundamental
- Price
- BIIB $160.63
- HBAN $18.01
- Analyst Decision
- BIIB Buy
- HBAN Buy
- Analyst Count
- BIIB 25
- HBAN 17
- Target Price
- BIIB $260.48
- HBAN $16.62
- AVG Volume (30 Days)
- BIIB 1.7M
- HBAN 15.3M
- Earning Date
- BIIB 10-30-2024
- HBAN 01-17-2025
- Dividend Yield
- BIIB N/A
- HBAN 3.44%
- EPS Growth
- BIIB 10.05
- HBAN N/A
- EPS
- BIIB 11.06
- HBAN 1.03
- Revenue
- BIIB $9,607,500,000.00
- HBAN $6,690,000,000.00
- Revenue This Year
- BIIB N/A
- HBAN N/A
- Revenue Next Year
- BIIB N/A
- HBAN $5.31
- P/E Ratio
- BIIB $14.52
- HBAN $17.48
- Revenue Growth
- BIIB N/A
- HBAN N/A
- 52 Week Low
- BIIB $153.62
- HBAN $11.21
- 52 Week High
- BIIB $268.30
- HBAN $18.45
- Technical
- Relative Strength Index (RSI)
- BIIB 33.97
- HBAN 69.03
- Support Level
- BIIB $156.09
- HBAN $17.36
- Resistance Level
- BIIB $160.63
- HBAN $18.33
- Average True Range (ATR)
- BIIB 3.99
- HBAN 0.33
- MACD
- BIIB 0.46
- HBAN -0.01
- Stochastic Oscillator
- BIIB 31.52
- HBAN 59.63
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HBAN Huntington Bancshares Incorporated
Huntington Bancshares Inc is a regional bank holding company headquartered in Columbus, Ohio. The bank operates in two business segments: Consumer & Regional Banking and Commercial Banking. The bank derives the maximum of its revenue from the Consumer & Business Banking segment. The other segment of the bank consists of Treasury and others. The bank also provides auto dealer, equipment finance, investment management, trust, brokerage, capital market services, and other services.